NORWALK, Conn., Nov. 1, 2016 /PRNewswire/ -- Mederi Therapeutics today announced that new 10-year patient follow-up data on Stretta therapy has been presented at this year's United European Gastroenterology Week ( UEGW) in Vienna, Austria. The data, from lead author Dr. Luca Dughera, University of Torino, Italy, showed significant, durable relief from GERD symptoms and elimination of PPI use in 71.9% of patients 10-years post-Stretta. Dr. Dughera's study was presented in the "Posters in the Spotlight Sessions", which recognized the best studies submitted to the congress.
The study followed 251 patients, including 57 patients who reached 10-year follow-up, and found a significant and durable effect of Stretta treatment. Findings included:
A significant improvement in both heartburn and GERD quality of life (HRQL) scores
71.9% (41/57) patients completely off PPIs 10-years after a Stretta procedure
Stretta was effective in resolving extra esophageal symptoms of GERD
About 30% of patients with GERD still experience symptoms despite standard medications such as Proton Pump Inhibitors (PPIs), and many more patients are concerned about potential risks of these long-term medications. Stretta is an ideal treatment for these patients who still have GERD despite medications but do not want to have surgery. Stretta is a non-surgical treatment that transorally (through the mouth) delivers low levels of radiofrequency (RF) energy to the muscle between the stomach and esophagus. Studies show that mechanisms of action include a thickening of the muscle and reduced tissue compliance, which improves the barrier function, resulting in fewer reflux events, reduced acid exposure and improved symptoms.